Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

382
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
382
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
Hormonal Regulation01:33

Hormonal Regulation

35.5K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
35.5K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

3.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

842
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
842
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.3K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subacute Dyspnea in a Young Woman with Newly Metastatic Breast Cancer.

Annals of the American Thoracic Society·2022
Same author

Central venous pressure and the risk of diuretic-associated acute kidney injury in patients after cardiac surgery.

American heart journal·2020
Same author

Effect of Intensive vs Standard Blood Pressure Treatment Upon Erectile Function in Hypertensive Men: Findings From the Systolic Blood Pressure Intervention Trial.

The journal of sexual medicine·2019
Same author

Safety-Net Care for Maintenance Dialysis in the United States.

Journal of the American Society of Nephrology : JASN·2019
Same author

Acute Kidney Injury in Children Hospitalized With Diarrheal Illness in the United States.

Hospital pediatrics·2019
Same author

A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation.

The journal of vascular access·2019
Same journal

Brain Iron in Nucleus Accumbens and Cognitive Function in Preeclampsia.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Hypertension Treatment Intentions: A Health Belief Model Analysis.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Changes in Retinal Microvasculature During Healthy Pregnancy Measured by AO.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Longitudinal Maternal IgG and IgA Glycosylation Profiles in Pregnancy Reveal Early Immune Alterations in Placenta-Related Complications: The Rotterdam Periconception Cohort.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Blood Pressure Variability and Outcomes Across Antihypertensive Regimens.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Rural Health and Health Disparities in Hypertension Management: A Scientific Statement From the American Heart Association.

Hypertension (Dallas, Tex. : 1979)·2026
See all related articles

Related Experiment Video

Updated: Dec 29, 2025

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.0K

Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study.

Gilad Jaffe1, Zachary Gray1, Gomathi Krishnan2

  • 1From the Stanford Hypertension Center (G.J., Z.G., M.S., G.M.C., V.B.), Stanford University School of Medicine, CA.

Hypertension (Dallas, Tex. : 1979)
|February 4, 2020
PubMed
Summary
This summary is machine-generated.

Screening for primary aldosteronism in resistant hypertension patients is low, with only 2.1% tested. This underuse of guideline-recommended screening may delay diagnosis and treatment of this secondary cause of high blood pressure.

Keywords:
aldosteronecardiovascular diseaseshypertensionrenin

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

598
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K

Related Experiment Videos

Last Updated: Dec 29, 2025

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.0K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

598
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Background:

  • Resistant hypertension increases cardiovascular and kidney disease risks.
  • Clinical guidelines recommend screening for primary aldosteronism in resistant hypertension.
  • Current screening rates for primary aldosteronism in this population are unknown.

Purpose of the Study:

  • To determine the screening rate for primary aldosteronism in patients with resistant hypertension.
  • To identify characteristics of screened versus unscreened patients.
  • To assess if medication use influenced screening rates.

Main Methods:

  • Retrospective cohort study of 4660 patients with resistant hypertension (2008-2014).
  • Identified patients meeting criteria for resistant hypertension with available lab tests.
  • Analyzed screening rates and patient demographics, clinical factors, and medication prescriptions.

Main Results:

  • Only 2.1% of eligible patients were screened for primary aldosteronism.
  • Screened patients were younger, had higher blood pressure, and lower coronary artery disease rates.
  • Medication prescribing patterns did not explain the low screening rates.

Conclusions:

  • Screening for primary aldosteronism in resistant hypertension is significantly underutilized.
  • Low screening rates are not attributable to interfering antihypertensive medications.
  • Increased awareness and implementation of guideline-recommended screening are necessary.